publication . Article . 2011

Randomize Trial of Cisplatin plus Gemcitabine with either Sorafenib or Placebo as First-line Therapy for Non-small Cell Lung Cancer

Yan WANG; Lin WANG; Yutao LIU; Shufei YU; Xiangru ZHANG; Yuankai SHI; Yan SUN;
Open Access Chinese
  • Published: 01 Mar 2011 Journal: Chinese Journal of Lung Cancer (issn: 1009-3419, eissn: 1999-6187, Copyright policy)
  • Publisher: Chinese Anti-Cancer Association; Chinese Antituberculosis Association
Background and objective Platinum-based chemotherapy doublets reached an efficacy plateau in nonsmall-cell lung cancer (NSCLC). This randomized controlled study prospectively assessed the efficacy and safety of cisplatin plus gemcitabine with either Sorafenib or placebo as first-line therapy for NSCLC. Methods Thirty patients, which were confirmed advanced NSCLC histologically or cytologically, were randomly assigned to receive up to six cycles of cisplatin plus gemcitabine with sorafenib or placebo. The maintenance of sorafenib or placebo after chemotherapy will continued in patients with response or stable disease until disease progression or unacceptable adve...
Medical Subject Headings: neoplasms
free text keywords: Lung neoplasms, Chemotherapy, Sorafenib, Response, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Download from
18 references, page 1 of 2

Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update. J Clin Oncol, 2004, 22(2): 330-353.

Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med, 2009, 361(10): 947-957. [OpenAIRE]

Herbst RS, Diane Prager, Robert Hermann, et al. TRIBUTE: a phase III trail of erlotinib hydrochloride (OSI-774) combined with carboplastin and paclitaxed chemotherapy in advanced NSCLC. J Clin Oncol, 2005, 23(25): 5892-5899.

Gatzemeier U, Pluzanska A, Szczesna A, et al. Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC). J Clin Oncol, 2004, 22(14S): 7010. [OpenAIRE]

Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III 6 7 8 9 10 11 12 13 14 15 16 17 18 trial--INTACT 1. J Clin Oncol, 2004, 22(5): 777-784.

Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial--INTACT 2. J Clin Oncol, 2004, 22(5): 785-794.

Janne PA, Wang XF, Socindki MA, et al. Randomized phase II trial of erlotinib (E) alone or in combination with carboplatin/paclitaxel (CP) in never or light former smokers with advanced lung adenocarcinoma: CALGB 30406. J Clin Oncol, 2010, 28: 15s (suppl; abstr 7503).

Wihelm SM, Adnane L, Newell P, et al. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinases signaling. Mol Cancer Ther, 2008, 7(10): 3129-3140. [OpenAIRE]

Carter CA, Chen C, Brink C, et al. Sorafenib is eficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinoma. Cancer Chemother Pharmacol, 2007, 59(2): 183-195.

Flahery KT, Schiller J, Schuchter LM, et al. A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel. Clin Cancer Res, 2008, 14(15): 4836-4842. [OpenAIRE]

Scagliotti G, Pawel J, Reck M, et al. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol, 2010, 28(11): 1810-1812. [OpenAIRE]

Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevaxizumab for non-small-cell lung cancer. N Engl J Med, 2006, 355(24): 2542-2550.

Laurie SA, Arnold A, Shepherd FA, et al. National Cancer Institute of Canada clinical trials group study BR.24, a randomized placebo controlled phase II trial of cediranib (CED) plus carboplatin+paclitaxel (C+P) in advanced nonsmall cell lung cancer of any histology: Further analyses. J Thorac Oncol, 2008, 3(suppl): S304.

Kim ES, Kies MS, Fosssella FV, et al. Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/ resistant non small cell luang carcinoma. Cancer, 2005, 104(3): 561-569. [OpenAIRE]

Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL. J Clin Oncol, 2009, 27(8): 1227-1234. [OpenAIRE]

18 references, page 1 of 2
Powered by OpenAIRE Open Research Graph
Any information missing or wrong?Report an Issue